Back to search
FDAFDA · Food and drugs·Recall number D-0115-2021

Levocetirizine Dihydrochloride Tablets, USP, 5 mg 30-count bottle, Rx Only, Distributed by: Marlex Pharmceuticals, Inc. New Castle, DE 19720. NDC 10135-0639-30

Published December 9, 2020 · Recall initiated: November 11, 2020

Summary

FDA records drug Class III recall D-0115-2021, published December 9, 2020 and initiated November 11, 2020. Recalling firm: InvaTech Pharma Solutions, LLC; Status: Terminated; Reported quantity: N/A; Lot: Lot #: 051944A Exp. Date April - 2021; 1119124 Exp Date Oct - 2021; 062088 Exp Date June - 2022. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: One lot of Levocetirizine dihydrochloride tablets 5 mg 30 count failed stability testing.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
InvaTech Pharma Solutions, LLC
Distributor
Distributed Nationwide in the USA
Lot
Lot #: 051944A Exp. Date April - 2021; 1119124 Exp Date Oct - 2021; 062088 Exp Date June - 2022;
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Levocetirizine Dihydrochloride Tablets, USP, 5 mg 30-count bottle, Rx Only, Distributed by: Marlex Pharmceuticals, Inc. New Castle, DE 19720. NDC 10135-0639-30 recalled?

Yes. FDA published recall D-0115-2021 on December 9, 2020. Reported hazard: Failed Impurities/Degradation Specifications: One lot of Levocetirizine dihydrochloride tablets 5 mg 30 count failed stability testing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter